Shares of WebMD (NASDAQ:WBMD) fall 12.2% premarket after the firm lowers its full-year revenue guidance and tips off a Q4 lining up to be disappointing. The firm doesn't expect to see the traditional late-year media buys from biopharmaceutical and consumer products customers.